gastroenterology News
-
Atmo exhibits at Australian Gastroenterology Week
Atmo Biosciences exhibited at Australian Gastroenterology Week Conference in Adelaide thanks to the generous support of C.R. Kennedy. CEO Mal Hebblewhite reported plenty of interest from gastroenterologists regarding the two clinical trials Atmo recently commenced with Professor Peter Gibson at Monash University. There was also lots of discussion about using the Atmo Gas Capsule as a research ...
-
Study results presented at AGW show Atmo Gas Capsule can be used to assess regional gastrointestinal transit in healthy adults
A Monash University comparative study has found Atmo Biosciences’ novel ingestible gas-sensing capsule to be similar to a validated wireless motility capsule (WMC) when assessing regional gastrointestinal transit time in healthy adults. Findings from the study, led by Professor Peter Gibson, are being presented in a poster at Australian Gastroenterology Week (AGW), being held virtually ...
-
Showcase
Atmo Biosciences awarded Australian Government grant to automate and scale-up manufacturing of ingestible gas-sensing capsule
Atmo Biosciences has been awarded an Australian Government Manufacturing Modernisation Fund (MMF) grant to support manufacturing automation and scale-up for the Atmo Gas-Sensing Capsule. The Round 2 MMF grants, part of the Government’s Modern Manufacturing Strategy, are for small-medium sized businesses to transform manufacturing and to support job growth and develop a more skilled ...
-
WATS3D AI Platform Included in American Gastroenterological Association (AGA) Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus
CDx Diagnostics, Inc. announced that the WATS3D view, published in Clinical Gastroenterology and Hepatology. WATS3D uses a unique wide-area sampling instrument, proprietary 3D imaging with AI analysis, and expert pathologists to reliably identify abnormal cells to help physicians prevent esophageal cancer. “The CPU is based on a thorough review of the existing clinical literature and ...
-
Iterative Scopes Partners with One GI to Advance Gastrointestinal Care Through Artificial Intelligence
Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI® will use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, ...
-
Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23
SG-5-00455, the Company’s development candidate for the treatment of IBD, aims to restore mucosal healing by targeting PAI-1/2 Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, today announced that it will host a virtual key opinion leader (KOL) event focused on the role of mucosal healing and ...
-
Iterative Health Redefines Approach to Precision GI Care
Iterative Health, formerly known as Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, has announced a rebrand to reflect the company’s success in utilizing artificial intelligence (AI) to strengthen clinical research and augment clinical decision making within gastroenterology. In this new chapter, Iterative Health will continue to focus on its core ...
-
CONMED Completes Acquisition of Biorez, Inc.
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced acquisition of privately-held Biorez, Inc. Biorez is a medical device start-up based in New Haven, CT and is focused on advancing the healing of soft tissue using its proprietary BioBrace® Implant technology. The BioBrace Implant is an innovative bioinductive ...
By Biorez Inc.
-
ANX ROBOTICA CORP RECEIVES 510(K) CLEARANCE FROM FDA TO MARKET ITS INTRAMARX™ RADIOPAQUE MARKERS
AnX Robotica Corp receives 510(k) clearance from FDA to market its IntraMarX™ Radiopaque Markers Plano, TX March 31st, 2020 – AnX Robotica Corp (AnX) today announced that it has received FDA 510(k) clearance to market its IntraMarX™ Radiopaque Markers (ROM). Radiopaque markers are used to measure colon transit time and they are the most basic and primary tool in evaluating ...
By AnX Robotica
-
Iterative Health Named to the 2022 CB Insights’ Digital Health 150 List
Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, today announced that it has been named one of CB Insights’ top 150 companies in Digital Health for 2022, the second year in a row in which it has made this list. The Digital Health 150 is CB Insights’ annual ranking of the 150 most promising digital health startups in the world. Iterative Health was ...
-
Built In Honors Iterative Health in Its Esteemed 2023 Best Places To Work Awards
Built In today announced that Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, was honored in its 2023 Best Places To Work Awards. Specifically, the company earned a place on the list of Boston’s Best Midsize Places to Work. The annual awards program includes companies of all sizes, from startups to those in the enterprise, and honors both remote-first ...
-
Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
Merck and Pfizer Inc. (NYSE: PFE) today announced topline results of the Phase III JAVELIN Gastric 100 study evaluating avelumab as first-line maintenance therapy following induction chemotherapy in patients with unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer versus continuation of chemotherapy or best supportive care. While the study ...
By Siemens AG
-
ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference
On the basis of clinical success and acknowledged leadership in the field of celiac disease, the organizers of the International Celiac Disease Symposium (ICDS) have invited Jack Syage PhD, CEO of ImmunogenX, to deliver a panel talk and join the Conference Faculty. ICDS is held internationally every other year and is considered the premier conference for celiac disease. This year it will be held ...
-
The Lancet Gastroenterology & Hepatology: Colorectal cancer incidence on the rise among young adults in several high-income countries
The incidence of colon and rectal cancer in adults younger than 50 years has increased substantially over the latest available 10-year period in several high-income countries, going against a decline or stabilisation trend in the incidence of colorectal cancers within the overall populations of high-income countries. This is according to an observational study published in The Lancet ...
By Siemens AG
-
Iterative Health Partners with Gastro Health to Accelerate Clinical Research in Gastroenterology Through Artificial Intelligence
Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. This strategic partnership will lay the groundwork for future collaborations by using AIR to aid ...
-
ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology
ImmunogenX is pleased to report the successful completion of the CeliacShield trial (NCT03585478), focused on treating celiac disease (CeD) patients, will be published in the premier journal Gastroenterology and is entitled: Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease Exposed to a Gluten Challenge doi.org/10.1053/j.gastro.2022.07.071 This ...
-
G-Tech Medical Receives FDA Clearance for its Gastrointestinal Motility Monitoring System
MOUNTAIN VIEW, Calif., January 13, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Wireless Patch System (WPS) for non-invasive myoelectric activity measurement. The G-Tech WPS is a tool that provides gastric and intestinal myoelectrical ...
-
Iterative Scopes Receives FDA Clearance for AI-Assisted Polyp Detection Device SKOUT
Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced today that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. SKOUT, a real-time ...
-
Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research
Rebiotix Inc, a Ferring Pharmaceuticals company, announced today that their Chief Scientific Officer, Dr. Ken Blount, has been appointed to Karolinska Institutet’s Joint Steering Committee (JSC) of the Centre for Translation Microbiome Research (CTMR) in Stockholm, Sweden. Dr. Blount joins two colleagues from Ferring Pharmaceuticals currently serving on the JSC – Per Falk, M.D., ...
-
Lumendi Introduces EZ Glide Hydrophilic Coating for Its DiLumen Endoluminal Interventional Platform (EIP)
Connecticut-based medical device innovator Lumendi, LLC (www.lumendi.com) has launched EZ Glide, a proprietary hydrophilic coating applied to the inner sheath of its DiLumen EIP, a double-balloon endoluminal device that aims to safely improve the navigation of the endoscope through the bowel, create a stabilizing therapeutic zone inside the colon during endoluminal interventions, ...
By Lumendi Ltd.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you